Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases

Cancer Journal

Volumn 16, Issue 2, 2010, Pages 132-141

  Alexander, H Richard ^a   Butler, Caroline C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN I 131; ALPHA INTERFERON; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; HEPARIN; IRINOTECAN; MELPHALAN; TUMOR NECROSIS FACTOR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CLOTTING DISORDER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOKINE PRODUCTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; HISTORY OF MEDICINE; HUMAN; IMMUNOSTIMULATION; ISOLATED HEPATIC PERFUSION CHEMOTHERAPY; LIVER METASTASIS; LIVER PERFUSION; MELANOMA; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; PANCYTOPENIA; PERCUTANEOUS HEPATIC PERFUSION CHEMOTHERAPY; PEROPERATIVE CARE; PRIORITY JOURNAL; REVIEW; SARCOMA; SIDE EFFECT; STOMACH TUMOR; SURGICAL TECHNIQUE; THERAPY EFFECT; THROMBOCYTOPENIA;

ANIMALS; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; COLORECTAL NEOPLASMS; HUMANS; LIVER NEOPLASMS;

EID: 77951461507     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3181db9c0a     Document Type: Review

References (33)

1. Breedis C, Young G. Blood supply of neoplasms of the liver. Am J Pathol. 1954;30:969-985.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71-96. (Pubitemid 351521864)
3. Ausman RK. Development of a technic for isolated perfusion of the liver. N Y State J Med. 1961;61:3393-3397.
4. Skibba JL, Quebbeman EJ. Tumoricidal effects and patient survival after hyperthermic liver perfusion. Arch Surg. 1986;121:1266-1271.
5. Skibba JL, Quebbeman EJ, Komorowski RA, et al. Clinical results of hyperthermic liver perfusion for cancer in the liver. Contr Oncol. 1988;29: 222-228.
6. Schwemmle K, Link KH, Rieck B. Rationale and indications for perfusion in liver tumors: current data. World J Surg. 1987;11:534-540. (Pubitemid 17137109)
7. Aigner KR, Walther H, Link KH. Isolated liver perfusion with MMC/5-FU- surgical technique, pharmacokinetics, clinical results. Contr Oncol. 1988;29: 229-246.
8. Hafström L, Rudenstam C-M, Holmberg SB, et al. The pharmacokinetics of melphalan in regional hyperthermic liver perfusion. Reg Cancer Treat. 1990;3:23-25. (Pubitemid 20367460)
9. Lienard D, Ewalenko P, Delmotti JJ, et al. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 1992;10:52-60.
10. Eggermont AMM, Koops HS, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. Ann Surg. 1996;224: 756-765.
11. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986;234:470-474.
12. Alexander HR, Feldman AL. Tumor necrosis factor: basic principles and clinical application in systemic and regional cancer treatment. In: Steven A, Rosenberg MD, eds. Biologic Therapy of Cancer. Philadelphia: Lippincott; 2000:174-193.
13. Rizell M, Mattson J, Cahlin C, et al. Isolated hepatic perfusion for liver metastases of malignant melanoma. Melanoma Res. 2008;18:120-126.
14. Alexander HR, Bartlett DL, Libutti SK. National Cancer Institute experience with regional therapy for unresectable primary and metastatic cancer of the liver or peritoneal cavity. In: Markman M, ed. Regional Chemotherapy: Clinical Research and Practice (Current Clinical Oncology). Totowa, NJ: Humana Press; 1999:127-150.
15. Alexander HR, Bartlett DL, Libutti SK, et al. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16:1479-1489.
16. Libutti SK, Bartlett DL, Fraker DL, et al. Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies. J Am Coll Surg. 2000;191:519-530.
17. Barker WC, Andrich MP, Alexander HR, et al. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs. Eur J Nucl Med. 1995;22: 1242-1248.
18. Alexander HR. Isolation perfusion. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. Philadelphia: Lippincott Williams & Wilkins; 2005:2316-2322.
19. Lans TE, Bartlett DL, Libutti SK, et al. Role of tumor necrosis factor (TNF) on toxicity and cytokine production following isolated hepatic perfusion (IHP). Clin Cancer Res. 2001;7:784-790.
20. Alexander HR Jr, Bartlett DL, Libutti SK, et al. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009;16:1852-1859.
21. van Iersel LB, Gelderblom H, Vahrmeijer AL, et al. Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol. 2008;19:1127-1134.
22. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Isolated hepatic perfusion for the treatment of patients with colorectal cancer liver metastases after irinotecan-based therapy. Ann Surg Oncol. 2005;12:138-144.
23. Alexander HR, Libutti SK, Bartlett DL, et al. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6: 3062-3070.
24. Alexander HR Jr, Libutti SK, Pingpank JF, et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2003;9:6343-6349.
25. Noter SL, Rothbarth J, Pijl ME, et al. Isolated hepatic perfusion with high-dose melphalan for the treatment of uveal melanoma metastases confined to the liver. Melanoma Res. 2004;14:67-72. (Pubitemid 38392417)
26. Grover AC, Libutti SK, Pingpank JF, et al. Isolated hepatic perfusion for the treatment of patients with advanced liver metastases from pancreatic and gastrointestinal neuroendocrine neoplasms. Surgery. 2004;136:1176-1182.
27. Rothbarth J, Tollenaar RA, Schellens JH, et al. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives. Eur J Cancer. 2004;40:1812-1824. (Pubitemid 39036755)
28. Pingpank JF, Libutti SK, Chang R, et al. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol. 2005;23:3465-3474.
29. Ravikumar TS, Pizzorno G, Bodden W, et al. Percutaneous hepatic vein isolation and high-dose hepatic arterial infusion chemotherapy for unresectable liver tumors. J Clin Oncol. 1994;12:2723-2736.
30. Curley SA, Newman RA, Dougherty T, et al. Complete hepatic venous isolation and extracorporeal chemofiltration as treatment for human hepatocellular carcinoma: a phase I study. Ann Surg Oncol. 1994;1:389-399.
31. Curley SA, Stone DL, Fuhrman GM, et al. Increased doxorubicin levels in hepatic tumors with reduced systemic drug exposure achieved with complete hepatic venous isolation and extracorporeal chemofiltration. Cancer Chemother Pharmacol. 1993;33:251-257.
32. Curley SA, Byrd DR, Newman RA, et al. Reduction of systemic drug exposure after hepatic arterial infusion of doxorubicin with complete hepatic venous isolation and extracorporeal chemofiltration. Surgery. 1993;114:579-585.
33. Farma JM, Pingpank JF, Alexander HR. Isolated hepatic perfusion: treating unresectable liver metastases. Adv Exp Med Biol. 2006;574:1-16.